Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) is a commercial-stage rare disease company whose news flow centers on its therapies for serious, low-prevalence conditions and the corporate developments that support these programs. The company regularly issues updates describing progress with its approved products, clinical pipeline, regulatory interactions, and financial performance.
A major theme in Zevra’s news is the commercialization and clinical evidence for MIPLYFFA (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC). Press releases highlight pivotal and long-term data, presentations at scientific and patient-focused meetings, and steps to broaden access, such as a distribution agreement with Uniphar to enable reimbursed named patient supply for NPC patients in select territories outside Europe. These items provide insight into how Zevra is working to expand the reach of its NPC treatment.
News coverage also includes updates on OLPRUVA (sodium phenylbutyrate), Zevra’s approved treatment for certain urea cycle disorders, and on celiprolol, its investigational candidate for vascular Ehlers-Danlos syndrome. The company reports on clinical trial enrollment milestones, publication of new analyses, and recognition of its scientific work at conferences, giving investors and clinicians visibility into the evolution of its rare disease portfolio.
In addition, Zevra issues quarterly financial results and corporate updates, detailing revenue contributions from its commercial products, operating expenses, and capital resources. Governance and organizational news, such as board appointments, executive transitions, and equity inducement grants under its employment inducement award plan, are disclosed through press releases and Form 8-K filings. For anyone tracking ZVRA, this news stream offers a consolidated view of the company’s therapeutic progress, regulatory status, and corporate trajectory in the rare disease space.
Zevra Therapeutics (Nasdaq: ZVRA) has announced a proposed underwritten public offering of its common stock. The company plans to offer all shares and grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price. Cantor and William Blair are acting as joint book-running managers. The offering is subject to market conditions, with no assurance of completion or final terms. It will be made through a prospectus supplement and accompanying prospectus filed with the SEC. This announcement does not constitute an offer to sell or solicitation of an offer to buy securities.
Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference in Boston, MA. Neil F. McFarlane, President and CEO of Zevra, will present on Wednesday, August 14, 2024, at 10:30 a.m. ET.
The executive team will be available for one-on-one investor meetings with registered attendees throughout the conference. Interested parties can access live webcasts of the presentation through the 'Events & Presentations' section of Zevra's website at investors.zevra.com.
Zevra Therapeutics (NasdaqGS: ZVRA) announced that the FDA's Genetic Metabolic Diseases Advisory Committee voted 11-5 in favor of arimoclomol's effectiveness in treating Niemann-Pick disease type C (NPC). The committee's recommendation will be considered by the FDA as it reviews the arimoclomol New Drug Application (NDA), with a PDUFA action date of September 21, 2024. Zevra's CEO, Neil F. McFarlane, expressed confidence in arimoclomol's clinical benefit based on data from the pivotal trial, long-term open-label extension study, and expanded access programs. The GeMDAC's decision, while not binding, is a positive step towards potential FDA approval for this rare disease treatment.
Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, has announced it will host a conference call and audio webcast on August 13, 2024, at 4:30 p.m. ET to review its corporate and financial results for the second quarter of 2024. The audio webcast will be accessible through the Investor Relations section of the company's website. Investors can join the meeting via conference call using the provided dial-in numbers. An archive of the webcast will be available for 90 days starting approximately at 5:30 p.m. ET on the same day.
Zevra Therapeutics announced that the FDA will review its New Drug Application (NDA) for arimoclomol on August 2, 2024. Arimoclomol is an oral treatment for Niemann-Pick disease type C (NPC), a rare genetic disorder. This review will be conducted by the Genetic Metabolic Diseases Advisory Committee (GeMDAC), newly formed by the FDA. The FDA plans to release background materials two business days before the meeting, and a Prescription Drug User Fee Act (PDUFA) action date has been set for September 21, 2024. Zevra's CEO, Neil F. McFarlane, emphasized the importance of this review for the NPC community, which lacks an approved therapy.
Zevra Therapeutics announced the appointment of Rahsaan W. Thompson as Chief Legal Officer, Secretary, and Compliance Officer, and Alison Peters as Chief People Officer. Both bring extensive experience to their roles, vital for Zevra's growth in rare disease therapeutics. Mr. Thompson, with over 25 years in the biotech sector, has vast expertise in corporate governance, SEC compliance, and litigation. Ms. Peters, with more than 20 years in human capital management, excels in talent acquisition and corporate culture. Additionally, both executives received inducement equity awards, with Mr. Thompson granted 200,000 restricted stock units and Ms. Peters 150,000, vesting over three years. These appointments are aligned with Zevra's strategic goals to enhance its commercial capabilities and advance its rare disease portfolio.
Zevra Therapeutics has partnered with Orsini Specialty Pharmacy as the new pharmacy provider for OLPRUVA® (sodium phenylbutyrate), used to manage certain urea cycle disorders (UCDs) in both adults and children. UCDs are rare genetic conditions that hinder the body's ability to eliminate excess ammonia, which can lead to severe neurological damage if untreated. OLPRUVA® helps mitigate this risk by acting as a nitrogen scavenger to remove excess ammonia. This collaboration aims to enhance access to OLPRUVA® for patients struggling with UCDs.
Zevra Therapeutics announced positive final results from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) at SLEEP 2024. KP1077 showed significant improvements in daytime sleepiness, sleep inertia, and brain fog with good tolerance across various doses. The European Commission granted Orphan Drug Designation for KP1077 for IH treatment. Key findings include substantial decreases in ESS, IHSS, SIVAS, and BFS scores, indicating notable clinical benefits. Additionally, pharmacokinetic data suggested effective morning and nighttime dosing without significant adverse events. These findings support initiating a Phase 3 trial.
Zevra Therapeutics, Inc. (ZVRA) will participate in several investor events in May 2024, with Neil F. McFarlane, the President and CEO, presenting at conferences in New York and Boston. The company aims to engage with investors and provide updates on their rare disease therapeutics.
Zevra Therapeutics, Inc. reported its Q1 2024 financial results, including $3.4 million in revenue, increasing R&D and SG&A expenses, a net loss of ($16.6) million, and a cash balance of $52.7 million. The Company refinanced its debt, securing up to $100 million in committed capital.